Skip to content
Research Article Open access CC BY 4.0

Novel Corona Virus (nCOVID-19; India): Chain Reaction Disease (CRD); Precaution-Prevention, Treatment A Review

Santosh A. Jadhav, Mahesh G. Shioorkar, Omprakash S. Chavan, Sunil G. Sabhadinde, Sangram B. Sonje, Devanand B. Shinde

International Journal of Biochemistry Research & Review · pp. 113–130 · Published 14 Dec 2020

10.9734/ijbcrr/2020/v29i930231

Abstract

Corona virus-2 (nCOVID-19), causes respiratory infection including cold, fever, sneezing and coughing, pneumonia, headache, diarrhea and upper respiratory diseases. It transmitted human to human via airborne droplets. Corona virus enters in human cell through membrane ACE-2 exopeptidase receptor. Corona virus (CV) previously it treated as non-fatal virus (NFV), HCoV-NH, SARS and MERS-CoV and SARS-CoV. It was first isolated from Wuhan market China at December 2019, in world thus its name nCOVID-19. It is a Chain Reaction Disease (CRD) because of tremendously spread through contact human to human. WHO and ECDC advised to avoid public place - social distance and close contact (person-person) to infected persons, airborne droplet through sneezing and coughing. Some precautions, preventions and treatment of formerly synthesized anti-malarial, anti-biotic and anti-inflammatory etc drug used on novel corona virus disease.

Flue influenza (FE) (1918) flu-like symptoms - CoV (1960) HCoV-NH MERS-CoV corona virus or SARS-CoV (2002-2005, 2012-2013) nCOVID-19 (2019) nCOVID-20(2020) chain reaction disease (CRD) treatment and precautions prevention India.

References (21)

  1. 1 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
  2. 2 First Case of 2019 Novel Coronavirus in the United States [DOI]
  3. 3 RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
  4. 4 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
  5. 5 Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study [DOI]
  6. 6 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [DOI]
  7. 7 Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area [DOI]
  8. 8 A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong [DOI]
  9. 9 [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. [DOI]
  10. 10 Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
  11. 11 Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China [DOI]
  12. 12 Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [DOI]
  13. 13 Severe Acute Respiratory Syndrome (SARS) in Singapore: Clinical Features of Index Patient and Initial Contacts [DOI]
  14. 14 A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 [DOI]
  15. 15 Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial [DOI]
  16. 16 Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak [DOI]
  17. 17 Global virus outbreaks: Interferons as 1st responders [DOI]
  18. 18 In vitro inhibition of human influenza A virus replication by chloroquine. [DOI]
  19. 19 Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003 [DOI]
  20. 20 Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy [DOI]
  21. 21 [Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro].

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

14

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.